论文部分内容阅读
日本自从2000年4月曲普坦类药物舒马普坦(IMIGRAN~)注射剂获准在医院使用以来,偏头痛的治疗发生了巨大的变革。很多偏头痛患者从曲普坦类药物中获益,其疗效得到高度评价。舒马普坦注射剂获准使用后,2001年6月其片剂、以及佐米普坦(ZOMIG~)片剂获准上市,偏头痛患者的院外急性期发作治疗又取得进展。2002年7月上市第三种曲普坦类药物依来曲普坦(RELPAX~)片剂,2003年7月又有了利扎曲普坦(MAX-ALT~)片剂,可选药物在逐渐增多。但是不容否认,由于用药方法不当,部分患者并没有获得良好疗效。此外有人称基于客观疗效评价来选择使用曲普坦类药物比较复杂。本文介绍各种曲普坦药物的区别、正确用药方法、以及最近的热门话题“异常性疼痛(allodynia)”。
Japan The treatment of migraine has undergone major changes since the application of the triptan sumatriptan injection (IMIGRAN ~ ) in hospitals in April 2000. Many migraine patients benefit from triptans and their efficacy is highly appreciated. Following the approved use of sumatriptan injection, the tablet and the ZOMIG-片 tablet were approved for marketing in June 2001 and further progress was made in the outpatient acute episode of migraine. In July 2002, the third triptan drug, RELPAX, was introduced. In July 2003, rizatriptan (MAX-ALT- Drugs are gradually increasing. However, it is undeniable that some patients did not receive good results due to improper medication methods. In addition, some people claim that the use of triptan based on objective evaluation of efficacy is more complicated. This article describes the differences between the various triptans, the correct medication, and the recent hot topic “allodynia.”